EyePoint Pharmaceuticals, Inc. Business Operations Contracts & Agreements
10 Contracts & Agreements
- Collaboration Agreements (2 contracts)
- Indemnification Agreements (5)
- Sales Agreements (2)
- Supply Agreements (1)
- Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 8, 2024)
- Commercial Supply Agreement, dated May 17, 2023, by and between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc (Filed With SEC on May 18, 2023)
- Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 14, 2022)
- Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 12, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 5, 2020)
- Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on August 7, 2019)
- At Market Issuance Sales Agreement, dated January 18, 2019, between EyePoint Pharmaceuticals, Inc. and B. Riley FBR, Inc (Filed With SEC on January 18, 2019)
- Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on September 18, 2018)
- Second Amended and Restated Collaboration Agreement by and between pSivida US Inc. and Alimera Sciences, Inc. dated July 10, 2017 (Filed With SEC on September 13, 2017)
- AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on May 12, 2008)
